Please assess the completion status of the following clinical trial:

Trial Title: Study of Ruxolitinib in Pancreatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosis of metastatic pancreatic cancer; subjects must have had measurable, or evaluable disease that was histologically confirmed~* Karnofsky performance status of ≥ 60~* Subjects must have failed 1st-line gemcitabine treatment for metastatic pancreatic cancer:~  o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy in the event that the subject was intolerant to or ineligible to receive gemcitabine~* ≥ 2 weeks elapsed from the completion of previous chemotherapy, and subjects must have recovered or been at new stable baseline from any related toxicities~Exclusion Criteria:~* More than 1 prior chemotherapy regimen (not including adjuvant therapy) for metastatic disease~* Evidence of central nervous system (CNS) metastases (unless stable for \> 3 months) or history of uncontrolled seizures~* Ongoing radiation therapy or prior radiation therapy administered as a second-line treatment~* Other active malignancy except basal or squamous carcinoma of the skin~* Inability to swallow food or any condition of the upper GI tract that precluded administration of oral medications~* Inadequate renal, hepatic and bone marrow function demonstrated by clinical observations and/or laboratory assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine and ruxolitinib (Type: EXPERIMENTAL): None
- Capecitabine and placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).